Erythropoietin (EPO) vs Nandrolone
Extensively Studied vs FDA Approved
monitor Mechanism-based · 60% Both Erythropoietin (EPO) and Nandrolone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Erythropoietin (EPO) Nandrolone
Weight 30,400 Da 274.40 Da (base)
Half-life 4-12 hours (IV), ~25 hours (SubQ) ~6-12 days (decanoate)
Chain 165 amino acids —
Type Glycoprotein hormone 19-nortestosterone steroid (C18H26O2)
Key Benefits
Erythropoietin (EPO)
01 Stimulates red blood cell production
02 Increases oxygen-carrying capacity
03 FDA-approved for anemia treatment
04 Improves endurance capacity
05 Supports patients with chronic kidney disease
06 Helps chemotherapy-induced anemia
07 Well-characterized mechanism of action
08 Extensively studied safety profile
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Dosing Protocols
Erythropoietin (EPO)
50-300 IU/kg based on medical indication / 1-3 times weekly depending on response
CKD Anemia (medical) 50-100 IU/kg 3x weekly
Chemotherapy Anemia (medical) 150-300 IU/kg 3x weekly
Maintenance (medical) Individualized 1-3x weekly
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Side Effects
Erythropoietin (EPO)
Injection site reactions
Headache
Hypertension
Joint pain
Flu-like symptoms
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Contraindications
Uncontrolled hypertension
Pure red cell aplasia history
Hemoglobin >12 g/dL (increased cardiovascular risk)
Active malignancy (relative contraindication)
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Research Evidence
Erythropoietin (EPO) Nandrolone
Status Extensively Studied FDA Approved
References 4 studies 5 studies
Latest — April 2005
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.